14 April 2025
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
12 March 2025
New data highlight the positive impact of Exact Sciences’ Oncotype DX® test on patient care and healthcare efficiency
10 December 2024
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
27 August 2024
Norway’s decision-making council for specialist health services (Nye Metoder) approves introduction of Oncotype DX® test to predict chemotherapy benefit for early breast cancer patients
9 May 2024
The National Institute for Health and Care Excellence (NICE) recommends use of Exact Sciences’ Oncotype DX® test to help guide chemotherapy decisions for node-positive breast cancer patients
1 December 2023
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium® Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
31 October 2023
Exact Sciences’ Oncotype DX Breast Recurrence Score® Test Receives IVDR CE Certificate
7 December 2022
Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022
28 April 2022
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
9 December 2021
New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making
2 December 2021
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
16 August 2021
Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan
20 May 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer
24 March 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the "Preferred" and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer
9 December 2020
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
2 October 2020
New Real-World Evidence Further Demonstrates the Clinical Utility of the Oncotype DX Breast Recurrence Score® Test, Beyond Clinical Risk Factors, in Guiding Chemotherapy Treatment Decisions in Patients with Early-stage Breast Cancer
29 May 2020
New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients
14 May 2020
New Oncotype DX Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
12 December 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
30 September 2019
New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment
21 August 2019
New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy for Node-Negative and Node-Positive Early-Stage Breast Cancer
21 June 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test
4 June 2019
Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
3 June 2019
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score Test in Node-negative Breast Cancer
25 March 2019
New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score Test to Target Chemotherapy
19 December 2018
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
New long-term evidence from large study reinforces value of the Oncotype DX Breast Recurrence Score test to guide adjuvant chemotherapy treatment, confirming TAILORx conclusions
New real-world evidence confirms utility of the Oncotype DX test in clinical practice for patients with early-stage breast cancer
German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® Has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving
New real-world clinical practice data reinforce the value of the Oncotype DX Breast Recurrence Score test for patients, physicians and the health care system
11 December 2017
New validation shows Oncotype DX Breast Recurrence Score test predicts clinical response to neoadjuvant hormonal therapy to improve surgical outcomes in certain patients with large tumors
11 September 2017
New analysis from German study group prospective trial shows minimal distant recurrence in patients with clinically high-risk breast cancer and low Oncotype DX Breast Recurrence Score results following five years of hormone therapy alone
12 July 2017
Updated St. Gallen International Breast Cancer Guidelines reinforce important role of genomic testing in treatment of early breast cancer
6 June 2017
New data show important role of genomic testing in treatment of older breast cancer patients
17 March 2017
Genomic Health unveils a wealth of data for the Oncotype DX breast cancer test, reinforcing its value in improving patient outcomes and leading to more cost-effective management
